Cytokinetics, Incorporated (CYTK)
Largest Insider Buys in Sector
CYTK Stock Price History Chart
CYTK Stock Performance
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase …
Insider Activity of Cytokinetics, Incorporated
Over the last 12 months, insiders at Cytokinetics, Incorporated have bought $0 and sold $30.84M worth of Cytokinetics, Incorporated stock.
On average, over the past 5 years, insiders at Cytokinetics, Incorporated have bought $3.23M and sold $22.27M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 118,413 shares for transaction amount of $1.13M was made by BVF PARTNERS L P/IL (10 percent owner) on 2019‑12‑11.
List of Insider Buy and Sell Transactions, Cytokinetics, Incorporated
| 2024-11-18 | Sale | President & CEO | 5,000 0.0041% | $50.55 | $252,750 | +0.75% | ||
| 2024-11-12 | Sale | EVP Research & Development | 6,342 0.0056% | $58.48 | $370,880 | -10.62% | ||
| 2024-11-01 | Sale | President & CEO | 5,000 0.0042% | $51.63 | $258,150 | +7.76% | ||
| 2024-10-30 | Sale | EVP Research & Development | 7,300 0.0063% | $51.91 | $378,930 | +8.17% | ||
| 2024-10-28 | Sale | director | 4,452 0.0036% | $52.25 | $232,617 | -0.19% | ||
| 2024-10-15 | Sale | EVP Research & Development | 7,300 0.0064% | $54.19 | $395,554 | -1.53% | ||
| 2024-10-09 | Sale | President & CEO | 5,000 0.0045% | $55.61 | $278,050 | +0.24% | ||
| 2024-10-01 | Sale | EVP Research & Development | 7,300 0.0061% | $52.10 | $380,297 | +3.67% | ||
| 2024-09-30 | Sale | President & CEO | 5,000 0.0042% | $52.14 | $260,700 | +3.25% | ||
| 2024-09-17 | Sale | EVP Research & Development | 7,300 0.0063% | $56.77 | $414,401 | -3.04% | ||
| 2024-09-16 | Sale | President & CEO | 5,000 0.0042% | $55.99 | $279,950 | -3.96% | ||
| 2024-09-09 | Sale | director | 5,000 0.0042% | $54.92 | $274,600 | -2.38% | ||
| 2024-09-03 | Sale | President & CEO | 5,000 0.0044% | $57.03 | $285,150 | -0.06% | ||
| 2024-09-03 | Sale | EVP Research & Development | 7,384 0.0066% | $57.01 | $420,973 | -0.06% | ||
| 2024-08-26 | Sale | director | 5,000 0.0043% | $57.26 | $286,300 | -3.83% | ||
| 2024-08-20 | Sale | EVP Research & Development | 7,300 0.0061% | $56.25 | $410,638 | -3.03% | ||
| 2024-08-12 | Sale | President & CEO | 11,500 0.0097% | $55.17 | $634,455 | -1.51% | ||
| 2024-08-12 | Sale | director | 5,000 0.0042% | $55.20 | $276,000 | -1.51% | ||
| 2024-08-06 | Sale | EVP Research & Development | 7,300 0.0062% | $53.71 | $392,090 | +3.34% | ||
| 2024-07-30 | Sale | President & CEO | 11,500 0.0097% | $59.49 | $684,135 | -2.66% |
Insider Historical Profitability
| HENDERSON JOHN T | director | 32070 0.0272% | $48.20 | 1 | 10 | +75.35% |
| SCHMERTZLER MICHAEL | director | 4340923 3.6783% | $48.20 | 1 | 8 | +68.65% |
| Eastern Capital LTD | 10 percent owner | 2883845 2.4436% | $48.20 | 1 | 0 | |
| DOW STEPHEN M | director | 1421052 1.2041% | $48.20 | 9 | 1 | <0.0001% |
| BVF PARTNERS L P/IL | 463244 0.3925% | $48.20 | 2 | 2 | +74.11% |
Institutional Investor Ownership
| BlackRock | $870.4M | 10.7 | 12.41M | -22.9% | -$258.52M | 0.02 | |
| Fidelity Investments | $764.28M | 9.39 | 10.9M | -16.2% | -$147.7M | 0.05 | |
| The Vanguard Group | $700.89M | 8.62 | 10M | -9.26% | -$71.5M | 0.01 | |
| T Rowe Price Investment Management Inc | $359.07M | 4.41 | 5.12M | +129.72% | +$202.77M | 0.22 | |
| Bank of America | $334.96M | 4.12 | 4.78M | +1,690.91% | +$316.26M | 0.03 |